Purchase this article with an account.
Romain NICOLAU, Sylvia Nghiem-Buffet, Franck FAJNKUCHEN, Salomon Yves Cohen, GABRIEL QUENTEL, Brigitte Guiberteau, Corinne Delahaye-Mazza, Gilles Chaine; Anti-VEGF For The Treatment Of Choroidal Neovascularization Secondary To Multifocal Choroiditis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5189.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Multifocal choroiditis (MFC) is an inflammatory condition, occasionally associated with choroidal neovascularization (CNV). To evaluate the efficacy and safety of intravitreal injections of ranibizumab or bevacizumab in choroidal neovascularization secondary to MFC.
Multicenter retrospective analysis of consecutive patients treated by intravitreal injections of ranibizumab or bevacizumab for naive choroidal vascularization in MFC. Patients received either one of 3 initial injections of ranibizumab 0,5 mg or bevacizumab 1,25mg then were retreated as needed based on montly controls including best-corrected visual acuity, spectral domain OCT and retinography.
9 Eyes of 9 patients (8 women) aged between 31 and 78 years ( mean age : MOYENNE) were included. 1 patient was treated with intravitreal injection of bevacizumab and 8 patients were treated with ranibizumab. Four patients received general corticotherapy as additive treatment.The mean number of antiVEGF injections was 3,9 (1-6) with a mean follow-up of 16 months (6-26).The mean visual acuity gain was of 9.5 (0-12). Eigth of nine eyes improved to 20/32 acuity or better at 6 months and the last eye improved to 20/40. Three eyes out of nine had recurrence of their CNV with a mean disease free interval of 5 months ( 3-8 months). No ocular or systemic adverse events were observed
Intravitreal antiVEGF results in an improvement of visual acuity in patients treated for CNV in CMF with a reduced number of injections and a limited number of recurrences.
This PDF is available to Subscribers Only